Phase I study of GSK461364, a specific and competitive Polo-like Kinase 1 (PLK1) inhibitor in patients with advanced solid malignancies.
D. Olmos, D. Barker, A. Sharma, A.T. Brunetto, T.A. Yap, A. Taegtmeyer, A.J. Allred, D.A. Smith, S.A. Murray, T.A. Lampkin, M.M. Dar, Richard Wilson, J.S. De Bono, S.P. Blagden
Research output: Contribution to journal › Article › peer-review